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Abstract
Background: Osteoblast differentiation requires the coordinated stepwise expression of multiple genes.
Histone deacetylase inhibitors (HDIs) accelerate the osteoblast differentiation process by blocking the
activity of histone deacetylases (HDACs), which alter gene expression by modifying chromatin structure.
We previously demonstrated that HDIs and HDAC3 shRNAs accelerate matrix mineralization and the
expression of osteoblast maturation genes (e.g. alkaline phosphatase, osteocalcin). Identifying other genes
that are differentially regulated by HDIs might identify new pathways that contribute to osteoblast
differentiation.
Results: To identify other osteoblast genes that are altered early by HDIs, we incubated MC3T3-E1
preosteoblasts with HDIs (trichostatin A, MS-275, or valproic acid) for 18 hours in osteogenic conditions.
The promotion of osteoblast differentiation by HDIs in this experiment was confirmed by osteogenic
assays. Gene expression profiles relative to vehicle-treated cells were assessed by microarray analysis with
Affymetrix GeneChip 430 2.0 arrays. The regulation of several genes by HDIs in MC3T3-E1 cells and
primary osteoblasts was verified by quantitative real-time PCR. Nine genes were differentially regulated
by at least two-fold after exposure to each of the three HDIs and six were verified by PCR in osteoblasts.
Four of the verified genes (solute carrier family 9 isoform 3 regulator 1 (Slc9a3r1), sorbitol dehydrogenase
1, a kinase anchor protein, and glutathione S-transferase alpha 4) were induced. Two genes (proteasome
subunit, beta type 10 and adaptor-related protein complex AP-4 sigma 1) were suppressed. We also
identified eight growth factors and growth factor receptor genes that are significantly altered by each of
the HDIs, including Frizzled related proteins 1 and 4, which modulate the Wnt signaling pathway.
Conclusion:  This study identifies osteoblast genes that are regulated early by HDIs and indicates
pathways that might promote osteoblast maturation following HDI exposure. One gene whose
upregulation following HDI treatment is consistent with this notion is Slc9a3r1. Also known as NHERF1,
Slc9a3r1 is required for optimal bone density. Similarly, the regulation of Wnt receptor genes indicates
that this crucial pathway in osteoblast development is also affected by HDIs. These data support the
hypothesis that HDIs regulate the expression of genes that promote osteoblast differentiation and
maturation.
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Background
Histone deacetylases (HDACs) and histone acetyltrans-
ferases participate in chromatin remodeling and the regu-
lation of gene expression. The opposing activities of these
enzymes alter chromatin structure by either adding or
removing acetyl groups from lysines in the amino-termi-
nal tails of histones. The addition of acetyl groups to his-
tones by acetyltransferases leads to the recruitment of co-
activators and the relaxation of chromatin conformation
that is necessary for transcriptional activation [1,2]. Con-
versely, removal of acetyl groups by HDACs results in a
condensed chromatin structure that is restrictive to tran-
scription. Mammalian HDACs are organized into four
classes. Class I HDACs (1, 2, 3, and 8) display nuclear
localization and ubiquitous tissue expression [3,4]. Class
II HDACs (4, 5, 6, 7, 9, and 10) exhibit tissue specific pat-
terns of expression, shuttle between the nucleus and cyto-
plasm, and are larger than class I HDACs [5]. Class III
HDACs (Sirt1-7) require the coenzyme NAD+ for enzy-
matic activity [6]. HDAC11 is the sole member of the new
Class IV [4].
HDAC inhibitors (HDIs) broadly compromise the activi-
ties of class I, II and IV HDACs, albeit with varying effi-
ciencies [7-9]. Natural and synthetic HDIs are divided into
several structurally diverse classes including hydroxamic
acids such as trichostatin A (TSA), short chain fatty acids
such as valproic acid (VPA) and sodium butyrate (NaB),
and benzamides such as MS-275 [10]. HDIs inhibit
HDAC activity by blocking a channel that leads to the
active site and a catalytic zinc ion [11]. In transformed
cells, HDIs induce growth arrest, apoptosis, and/or differ-
entiation via many mechanisms [7,10]. HDIs are currently
in clinical trials as anticancer agents [10,12]; they are also
established antiepileptic drugs [13] and potential treat-
ments for inflammatory and cardiac diseases [14,15].
There are comparatively fewer data on the effects of HDIs
on normal cells; however, the existing evidence suggests
that normal cells are resistant to the anti-proliferation,
pro-apoptosis and pro-differentiation effects of HDIs
because their cell cycle checkpoints are intact [16,17].
We previously demonstrated that concentrations of TSA,
MS-275 and VPA that were sufficient to induce histone H3
hyperacetylation in primary and MC3T3-E1 osteoblasts
modestly increased cell proliferation and viability but had
no effect on cell cycle progression [18]. More strikingly,
HDIs accelerated the osteoblast maturation process by
several days. Thus, short-term exposure to TSA accelerated
the appearance of alkaline phosphatase activity and
matrix mineralization as well as expression of type I colla-
gen, osteopontin, bone sialoprotein, and osteocalcin
genes in MC3T3-E1 cell cultures [18]. TSA, MS-275 and
NaB also increased alkaline phosphatase activity in calvar-
ial organ cultures [18]. Other studies showed that HDIs
increase expression of genes associated with osteoblast
maturation [19-22], enhance mineralization [21], block
glucocorticoid-induced cell cycle arrest in osseous cells
[23], and stimulate osteoblast differentiation of multipo-
tent mesenchymal cells [24,25]. Suppression of HDAC1
or HDAC3 by RNA interference also accelerated osteoblast
maturation [22,26]. These results suggest that the gene
expression changes occur upon inhibition of HDACs and
promote osteoblast terminal differentiation. In this study,
we used an unbiased approach to identify osteoblast
genes that are altered by HDIs within 18 hours to obtain
a better understanding of the early pathways involved in
accelerating the osteogenic phenotype.
Results
HDIs increase alkaline phosphatase activity during 
osteoblast differentiation
We previously demonstrated that HDIs accelerate and
enhance alkaline phosphatase expression by MC3T3-E1
pre-osteoblasts after three days. By the second week, the
HDI-exposed cultures expressed higher levels of genes
associated with osteoblast differentiation (e.g. bone siaol-
oprotein, osteopontin and osteocalcin) than control cells
[18]. The goal of this study was to identify genes that are
affected early (within the first 18 hours) by several HDIs
because they are more likely to be initiators or early regu-
lators of the process. To demonstrate the differentiation
potential of the HDI and vehicle-treated cells used in the
microarray experiment, cells in parallel cultures were
allowed to differentiate for up to seven days. During the
differentiation process, lysates were taken at days 0, 1, 4,
and 7 and alkaline phosphatase activity was measured. In
the DMSO-treated cells, alkaline phosphatase activity
increased steadily over time demonstrating that the cells
were differentiating appropriately (Figure 1). Alkaline
phosphatase activity also increased in the HDI-treated
cells and was generally higher in HDI-exposed cells rela-
tive to vehicle-treated cells at days 4 and 7 (Figure 1).
These results demonstrate that the MC3T3 cells used for
microarray analysis differentiated appropriately and that
the HDIs accelerated differentiation as expected from our
previous studies [18].
Gene expression profiles of HDI treated cells
To determine the molecular mechanisms whereby HDIs
accelerate osteoblast maturation, we used microarray
analysis to compare gene expression changes in MC3T3-
E1 cells treated with HDIs or its vehicle, dimethylsulfox-
ide (DMSO). On the basis of our previous studies wherein
we examined the expression changes in candidate genes
after three days of HDI exposure [18], we hypothesized
that HDI treatment at the beginning of differentiation
would reprogram gene expression and accelerate the
entire differentiation process. To identify the relatively
early changes in gene expression that occur in response toBMC Genomics 2007, 8:362 http://www.biomedcentral.com/1471-2164/8/362
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HDIs in differentiating cells, we isolated RNA from
MC3T3-E1 cells cultured in osteogenic medium and HDIs
for only 18 hours. Corresponding probes were hybridized
to Affymetrix GeneChip arrays and subjected to bioinfor-
matics analyses.
At a false discovery rate (FDR) of 0.01 (99% confidence)
relative to the vehicle (DMSO)-treated cells, 6117 genes
were differentially expressed in the TSA-treated cells, 846
genes in the MS-275-treated cells, and 117 genes in the
VPA-treated cells. The top 70 TSA-regulated genes, all
altered by more than five-fold, are listed in Table 1. The
genes altered more than two-fold by MS-275 and VPA are
shown in Tables 2 and 3, respectively. The complete raw
data sets have been deposited at the NCBI in the Gene
Expression Omnibus data repository (GEO series record
GSE9247) [27].
To compare the differentially expressed genes in all three
HDI treatments relative to DMSO, Venn analysis was per-
formed (Figure 2). Of the 29 genes differentially regulated
by all three HDIs, 21 were induced and eight were sup-
pressed (Table 4). Only four of these 29 genes were differ-
entially regulated more than two-fold by each of the three
HDIs (Table 5). Three of these four genes were induced;
they are solute carrier family 9 isoform 3 regulator 1
(Slc9a3r1), glutaminyl-peptide cyclotransferase (Qpct),
and sorbitol dehydrogenase I (Sdh1). These genes are not
affected by TSA in NIH3T3 cells, suggesting specificity to
osteoblasts (Figure 3). The suppressed gene is proteasome
subunit beta type 10 (Psmb10). This gene was also down-
regulated by TSA in NIH3T3 cells, indicating that it was
not specifically targeted in the osteoblasts. When the FDR
was changed to 0.05 (95% confidence), four additional
genes were altered more than two-fold by each of the three
HDIs (Table 5). Three genes (A kinase anchor protein 12
(Akap12), Glutathione S-transferase alpha 4 (Gsta4), and
Ral GEF with a PH domain and SH binding motif 2
(Ralgps2)) were induced by the HDIs and one gene, Adap-
tor-related protein complex AP-4 sigma 1 (Ap4s1), was
suppressed.
The temporal regulation of several identified genes was
determined by quantitative real-time PCRs using mRNAs
isolated from independent cultures of MC3T3 cells or pri-
mary murine calvarial osteoblasts. Consistent with the
GeneChip analysis, TSA was a more potent inducer of
Slc9a3r1 than MS-275 or VPA in both MC3T3 cells (Figure
4A) and primary osteoblasts (Figure 4B). Slc9a3r1 induc-
tion was detectable at both the RNA and protein levels as
early as 4 to 6 hours after HDI exposure (Figure 4B and
4E). Similar effects were observed with Sdh1 mRNA in
both MC3T3 (Figure 4C) and primary osteoblasts (Figure
4D) except VPA induced a more rapid increase in Sdh1
expression than TSA. The induction of Akap12 was also
confirmed in primary osteoblasts (data not shown). The
suppression of Psmb10 and Ap4s1 was confirmed in pri-
mary osteoblasts (Figure 5).
Regulation of growth factor and growth factor receptor 
genes by HDIs
We previously demonstrated that HDIs induced the differ-
entiation rate of MC3T3 cells and primary calvarial oste-
oblasts [18]. Therefore we analyzed the microarray data
sets for growth factor and growth factor receptor genes
that were differentially regulated by MS-275, VPA and TSA
with greater than 95% confidence. Of the eight genes
identified, only three were induced by all of the HDIs
(Table 6). Amphiregulin, a preostoblast growth factor
[28], was most consistently and highly increased. Brain-
derived neurotrophic factor and the Wnt/Norrin receptor,
Frizzled 4 (Fz4), were also stimulated by HDIs. In con-
trast, Fz1, an antagonist of osteoblast growth [29], was
suppressed by HDIs. Quantitative real-time PCR analyses
verified the differential regulation of several of these genes
in primary osteoblasts (Table 6) and MC3T3 cells (data
not shown).
Discussion
HDIs are potential bone anabolic agents due to their abil-
ity to promote osteoblast maturation and osteo-progeni-
tor expansion [18,21,22,24,25]. We previously showed
that the addition of HDIs to MC3T3 cell cultures for three
HDI treatment accelerates the appearance of alkaline phos- phatase activity in differentiating MC3T3 cells Figure 1
HDI treatment accelerates the appearance of alka-
line phosphatase activity in differentiating MC3T3 
cells. MC3T3 cells were cultured for the indicated times in 
osteogenic medium. The medium was changed three days 
with the HDIs or vehicle added only at day 0. Fold change in 
ALP activity is shown in relation to values obtained at the 
start of the culture (day 0). * denotes a statistically significant 
change of p < 0.01 by one-way ANOVA of the HDI-treated 
sample versus the DMSO-treated sample at that time point.BMC Genomics 2007, 8:362 http://www.biomedcentral.com/1471-2164/8/362
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Table 1: Top 70 known genes altered by TSA in MC3T3-E1 cells
Gene Fold Change Welch Test
Induced
Ubiquitin carboxy-terminal hydrolase L1 12.66 6.79E-06
Clusterin 12.58 1.80E-05
A kinase (PRKA) anchor protein (gravin) 12 9.431 1.06E-07
Abhydrolase domain containing 3 9.089 1.36E-05
Protease, serine, 35 9.058 3.48E-06
Glutathione S-transferase, alpha 4 8.408 3.35E-08
Amphiregulin 7.100 2.57E-06
Rab40b, member RAS oncogene family 6.904 1.16E-06
Thioredoxin interacting protein 6.865 1.61E-06
Apolipoprotein L, 2 6.604 0.001083
Laminin, alpha 1 5.616 1.70E-04
Solute carrier family 9, isoform 3 regulator 1 5.565 2.32E-05
Growth arrest and DNA-damage-inducible 45 alpha 5.422 3.67E-06
Insulin-like 6 5.418 6.71E-05
Thrombospondin 1 5.374 1.07E-04
Aldehyde dehydrogenase family 1, subfamily A7 5.359 4.73E-04
Erythrocyte protein band 4.1-like 5 5.266 6.39E-04
Hemoglobin alpha, adult chain 1 5.119 2.93E-06
Glutaminyl-peptide cyclotransferase (glutaminyl cyclase) 5.046 1.22E-05
Suppressed
SMC4 structural maintenance of chromosomes 4-like 1 -5.192 5.96E-04
Kinesin family member 11 -5.266 1.07E-08
Lysyl oxidase -5.284 1.66E-06
Antigen identified by monoclonal antibody Ki 67 -5.293 3.76E-04
Prostaglandin F receptor -5.296 6.12E-04
Proteasome (prosome, macropain) subunit, beta type 10 -5.362 4.16E-04
Ubiquitin-conjugating enzyme E2C -5.393 8.64E-06
Cyclin B1, related sequence 1 -5.408 1.21E-05
Cytoskeleton associated protein 2 -5.441 1.47E-07
Polo-like kinase 4 -5.456 1.03E-08
Chromodomain helicase DNA binding protein 3 -5.528 6.74E-04
Hyaluronan mediated motility receptor (RHAMM) -5.547 5.41E-04
Kinesin family member 23 -5.605 2.30E-06
Epithelial membrane protein 3 -5.606 3.65E-05
Proteasome 26S subunit, ATPase 3, interacting protein -5.623 5.01E-04
Cell division cycle 2 homolog A (S. pombe) -5.693 1.43E-05
Formyltetrahydrofolate synthetase domain containing 1 -5.725 1.96E-04
Nucleolar and spindle associated protein 1 -5.780 1.81E-05
Centromere autoantigen A -5.840 2.79E-04
Fibroblast growth factor 7 -5.856 6.42E-06
c-Fos induced growth factor -5.931 1.99E-04
High mobility group box 2 -6.108 2.44E-08
Similar to G2/mitotic-specific cyclin B1 -6.166 1.07E-05
Cyclin A2 -6.311 3.35E-08
Cell division cycle associated 2 -6.395 3.47E-05
Calmodulin-like 4 -6.400 7.64E-04
Heat shock protein, alpha-crystallin-related, B6 -6.401 1.69E-04
Mannan-binding lectin serine protease 1 -6.413 3.19E-05
UDP glycosyltransferase 1 family, polypeptide A6 -6.498 8.67E-04
Calmodulin binding protein 1 -6.501 1.68E-08
Aurora kinase B -6.531 1.74E-05
PDZ binding kinase -6.548 3.16E-08
Minichromosome maintenance deficient 5 -6.613 6.08E-08
Interleukin 1 receptor-like 1 -6.641 6.40E-08
RAD51 associated protein 1 -6.877 9.26E-05
Centromere protein E -6.911 3.17E-04
F-box only protein 5 -7.052 1.79E-07BMC Genomics 2007, 8:362 http://www.biomedcentral.com/1471-2164/8/362
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or six days accelerated the expression of known early and
late osteoblast differentiation genes [18]. To identify
genes affected early by the HDIs, we differentiated and
treated MC3T3-E1 cells with three HDIs or vehicle for 18
hours and analyzed gene expression profiles with Affyme-
trix microarray gene chips. Relative to vehicle-treated cells,
TSA altered the expression of 6117 genes; MS-275 altered
846 genes; and VPA changed 117 genes. The large differ-
ences between the numbers of genes affected by the HDIs
may be due to differences in their potencies, half-lives
and/or specificities. Nanomolar concentrations of TSA
inhibit the activities of all HDACs [7]. Likewise, MS-275 is
effective at nanomolar concentrations; however, it does
not inhibit HDAC8 [9]. In contrast, VPA is effective at mil-
limolar concentrations and specifically inhibits class I and
II HDACs with the exceptions of HDAC6 and HDAC10
[8]. Tables 2, 3, 4 list the genes most differentially regu-
lated by each HDI. As indicated in the Venn diagram (Fig-
ure 2), some genes on these lists are affected by just one
HDI. These genes might appear just in one group because
we only assayed one time point; however, it is possible
that each HDI affects a distinct subset of genes, some of
which might not affect osteoblast differentiation. These
differences could affect the suitability of an HDI for a spe-
cific application.
All three HDIs (TSA, MS-275 and VPA) used in this study
accelerate MC3T3 terminal differentiation and induce
alkaline phosphatase activity in calvarial organ cultures
[18]. Genes significantly altered by all three HDIs may
represent a core group of genes that are responsible for ini-
tiating the acceleration of osteoblast differentiation. Of
note, well-known osteoblast genes, such as osteocalcin,
did not appear in our results. It is likely that the time of
analysis (18 hours) was too early to see differential effects
on these genes. Of the most differentially regulated genes
(Table 5), Slc9a3r1 is the most likely to have roles in oste-
oblast proliferation and/or differentiation.
Slc9a3r1, also known as Na+/H+ exchanger regulatory fac-
tor (NHERF) or ezrin binding protein 50, is an apical
membrane phosphoprotein that links membrane pro-
teins with cytoplasmic proteins to regulate actin cytoskel-
etal reorganization [30]. Slc9a3r1 interacts with
numerous signaling proteins [31], including the G-pro-
tein coupled receptor for parathyroid hormone [32], and
the canonical Wnt signal transducer, β-catenin [33];
thereby implicating its potentially important role in oste-
oblast maturation. Slc9a3r1 (NHERF-1) deficient mice
develop renal phosphate wasting, but the majority of
female mice also had a 25–30% reduction in bone min-
eral density and a 40% decrease in bone mineral content
with multiple fractures [34]. We found that overexpres-
sion of Slc9a3r1 in osteoblasts by adenoviral transduction
was not sufficient to drive osteoblast differentiation (data
not shown). These data indicate that NHERF-1 contrib-
utes to bone homeostasis but is not sufficient to promote
osteoblast maturation.
Another differentially regulated gene is proteasome subu-
nit beta type 10 (Psmb10). Also known as Lmp10 and
MECL1, Psmb10 was suppressed by HDIs in both MC3T3
osteoblasts and NIH3T3 cells. Psmb10 is one of ten prote-
olytically-active beta subunits of the 20S core complex
within the 26S proteosome [35]. Ubiquitin-mediated pro-
teasomal degradation has an established role in osteob-
lasts [36,37]. Compounds that bind to the 20S
proteasome beta subunits, inhibit the ubiquitin-proteas-
ome pathway and stimulate bone formation in vitro and
in vivo [36]. Therefore, the decreased expression of
Psmb10 upon HDI treatment is consistent with the
observed acceleration of osteoblast differentiation. The
specific role HDAC activity plays in the regulation of
Psmb10 expression is unclear. The non-specific decreased
expression of this gene upon HDI treatment suggests that
the Psmb10 promoter is probably not directly regulated
Serine/threonine kinase 6 -7.090 1.10E-07
Stem cell growth factor -7.199 6.95E-05
Proline 4-hydroxylase, alpha polypeptide III -7.383 3.66E-07
Cell division cycle 20 homolog -7.469 1.27E-04
Asporin -7.618 6.15E-04
Glutathione peroxidase 7 -8.216 1.26E-07
Polo-like kinase 1 -8.301 9.95E-06
Sushi-repeat-containing protein -8.701 5.38E-08
Ribonucleotide reductase M2 -9.796 2.00E-04
Chromosome condensation 1-like -9.845 6.69E-04
Histone 1, H2ad -10.21 4.61E-06
Procollagen, type III, alpha 1 -10.44 6.38E-04
Matrix metalloproteinase 13 -11.09 3.70E-05
Thymidine kinase 1 -16.96 2.88E-05
All genes were present at a FDR of 0.01 (99% confidence) relative to the vehicle control, DMSO. The list excludes ESTs and other non-annotated 
sequences.
Table 1: Top 70 known genes altered by TSA in MC3T3-E1 cells (Continued)BMC Genomics 2007, 8:362 http://www.biomedcentral.com/1471-2164/8/362
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by HDACs but rather through a repressor whose expres-
sion is sensitive to HDAC activity.
We previously reported that HDIs induce the proliferation
and/or survival of MC3T3 cells and primary calvarial oste-
oblasts but do not affect cell cycle progression [18]. Exam-
ination of the microarray gene lists for growth factor and
growth factor receptor genes affected by HDIs identified
eight genes that could influence osteoblast growth, but
only three were increased. Amphiregulin was highly
induced by HDIs (Table 6). Amphiregulin binds EGF
receptors and is a potent growth factor for preosteoblasts
[28]. Brain derived neurotrophic factor mRNA was also
increased by HDIs, but its effects on osteoblast growth
have not been determined. Two Frizzled genes were also
regulated by HDIs. Frizzled-4 was increased by HDIs,
while Frizzled-1 levels were suppressed. Frizzled-4 is a
receptor for Norrin [38] and presumably Wnts, which pro-
mote osteoblast progenitor proliferation and survival
[39]. In contrast, murine Frizzled-1 is a negative regulator
of bone formation [29]; thus its suppression is consistent
with differentiation promotion by HDIs. No other com-
Table 2: Top 40 known genes altered by MS-275 in MC3T3-E1 cells
Gene Fold Change Welch Test
Induced
AMP deaminase 3 4.177 1.93E-06
Musculoskeletal, embryonic nuclear protein 1 3.427 1.35E-05
Adenylosuccinate synthetase like 1 3.038 4.20E-05
Amphiregulin 2.710 4.64E-05
Lysyl oxidase 2.697 1.92E-06
Colony stimulating factor 1 (macrophage) 2.694 9.32E-05
Fatty acid binding protein 4, adipocyte 2.518 4.52E-05
Chemokine (C-C motif) ligand 9 2.505 4.00E-05
Solute carrier family 9 isoform 3 regulator 1 2.477 3.63E-06
Sorbitol dehydrogenase 1 2.431 1.89E-07
Troponin C, cardiac/slow skeletal 2.408 6.23E-05
Proline arginine-rich end leucine-rich repeat 2.391 2.05E-05
Glutaminyl-peptide cyclotransferase (glutaminyl cyclase) 2.387 7.24E-05
Inhibitor of DNA binding 1 2.358 1.24E-05
Solute carrier family 40, member 1 2.275 1.04E-04
Glutathione S-transferase, alpha 4 2.268 3.40E-07
Septin 4 2.195 9.94E-05
Voltage-dependent calcium channel gamma subunit-like 2.187 4.78E-05
Immediate early response 3 2.171 4.22E-06
Dimethylarginine dimethylaminohydrolase 1 2.165 1.49E-06
Similar to Normal mucosa of esophagus specific gene 1 2.157 2.91E-06
MAS-related GPR, member F 2.122 1.15E-04
Microtubule-associated protein tau 2.101 9.32E-06
Retinoic acid induced 3 2.095 1.92E-05
High mobility group AT-hook 1 2.088 7.18E-05
A disintegrin-like and metalloprotease with thrombospondin type 1 motif, 5 2.088 7.60E-05
Connective tissue growth factor 2.075 3.62E-05
A kinase (PRKA) anchor protein (gravin) 12 2.036 1.78E-05
Aldehyde dehydrogenase family 3, subfamily A1 2.029 1.25E-04
Galactokinase 2 2.017 2.88E-06
Dystrophia myotonica kinase, B15 2.014 3.81E-05
Thrombospondin 1 2.005 7.11E-05
Suppressed
Proline 4-hydroxylase, alpha polypeptide III -2.006 4.79E-06
Interleukin 1 receptor-like 1 -2.035 4.28E-06
Proteasome (prosome, macropain) subunit, beta type 10 -2.063 2.96E-06
Guanylate nucleotide binding protein 2 -2.284 2.04E-06
Transcription factor AP-2 beta -2.299 2.27E-05
Sirtuin 1 -2.450 6.21E-05
Adaptor-related protein complex AP-4, sigma 1 -2.484 1.97E-06
All genes were present at a FDR of 0.01 (99% confidence) relative to the vehicle control, DMSO. The list excludes ESTs and other non-annotated 
sequences.BMC Genomics 2007, 8:362 http://www.biomedcentral.com/1471-2164/8/362
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Table 3: Top 10 known genes altered by VPA in MC3T3-E1 cells
Gene Fold Change Welch Test
Induced
Glutathione S-transferase, theta 1 2.345 1.73E-06
Glutaminyl-peptide cyclotransferase 2.334 2.36E-05
Sorbitol dehydrogenase 1 2.328 1.91E-06
Procollagen, type XI, alpha 1 2.216 7.84E-06
Solute carrier family 9, isoform 3 regulator 1 2.203 2.33E-06
Suppressed
Proteasome subunit, beta type 10 -2.035 3.33E-06
Adaptor-related protein complex AP-4, 
sigma 1
-2.119 4.39E-07
RIKEN cDNA 2310039E09 gene -2.759 1.48E-05
Tenascin N -2.913 8.53E-06
Chemokine (C-X-C motif) receptor 6 -3.728 1.56E-07
All genes were present at a FDR of 0.01 (99% confidence) relative to the vehicle control, DMSO.
Table 4: Genes differentially regulated by all three HDIs
Gene Description TSA MS-275 VPA
Induced Fold Change
Thioredoxin interacting protein 6.865 1.530 1.404
Solute carrier family 9, isoform 3 regulator 1 5.565 2.477 2.203
Glutaminyl-peptide cyclotransferase (glutaminyl cyclase) 5.046 2.387 2.334
Sorbitol dehydrogenase 1 4.455 2.431 2.328
Histocompatibility 2, Q region locus 5 4.009 1.634 1.820
Phosphomannomutase 1 3.895 1.902 1.808
RAB3D, member RAS oncogene family 3.717 1.528 1.742
Cbp/p300-interacting transactivator 3.458 1.658 1.321
Protease, serine, 11 3.326 1.836 1.744
Syntaxin 11 2.488 1.942 1.750
Protein phosphatase 1, regulatory (inhibitor) subunit 14c 2.484 1.347 1.830
Lysosomal-associated protein transmembrane 4B 2.366 1.503 1.637
Similar to normal mucosa of esophagus specific gene 1 2.099 2.157 1.930
F-box and leucine-rich repeat protein 16 2.019 1.746 1.561
HIV-1 Rev binding protein 1.953 1.406 1.414
Heat shock 70 kDa protein 5 binding protein 1 1.946 1.358 1.589
Cysteine rich protein 2 1.929 1.847 1.773
Asparagine synthetase 1.597 1.451 1.248
Serum deprivation response 1.485 1.517 1.676
Thymus cell antigen 1, theta 1.419 1.638 1.676
Ribonuclease, RNase A family 4 1.341 1.341 1.529
Suppressed
Interleukin 1 receptor-like 1 -1.634 -2.035 -1.831
Low density lipoprotein receptor -2.487 -1.282 -1.377
Proteolipid protein 2 -2.717 -1.274 -1.233
PHD finger protein 15 -4.100 -1.498 -1.613
Vesicle-associated membrane protein 8 -4.130 -1.417 -1.500
Proteasome (prosome, macropain) subunit, beta type 10 -5.362 -2.063 -2.035
Chromosome condensation 1-like -7.016 -1.514 -1.721
Glutathione peroxidase 7 -8.216 -1.768 -1.972
All genes were present at a FDR of 0.01 (99% confidence) relative to the vehicle control, DMSO.BMC Genomics 2007, 8:362 http://www.biomedcentral.com/1471-2164/8/362
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ponents of the Wnt signaling pathway were significantly
regulated by all HDIs at the 18-hour time point.
Conclusion
We identified many osteoblast genes whose expression
levels are altered by HDIs. All genes we have tested to date
are similarly differentially regulated in both MC3T3-E1
cells and primary murine calvarial osteoblasts. These data
improve our understanding of how HDIs promote oste-
oblast differentiation by identifying genes that are altered
within the first 18 hours of HDAC inhibition.
Methods
Cell culture
MC3T3-E1 preosteoblasts were plated at 2 × 105 cells per
6-cm plate and 4 × 104 cells per well of a 12-well plate and
differentiated in Minimal Essential Medium (Invitrogen,
Carlsbad, CA) containing 10% FBS (Invitrogen and Cam-
brex Bioscience/Lonza, Basel. Switzerland), 100 U/ml
penicillin, 100 µg/ml streptomycin, 50 µg/ml ascorbic
acid, 10 mM β-glycerol phosphate and one of the follow-
ing compounds: 20 nM TSA (Sigma, St. Louis, MO), 500
nM MS-275 (Calbiochem, San Diego, CA), 500 mM VPA
(Sigma), or DMSO (vehicle). During the differentiation
assay, the osteogenic medium was replaced every three
days with the HDIs or vehicle added only at day 0. C2C12
cells and NIH3T3 fibroblasts were maintained Dulbecco's
modified Eagle's medium containing 10% FBS, 100 U/ml
penicillin and 100 µg/ml streptomycin. Primary calvarial
osteoblasts were isolated as previously described [18].
Briefly, calvaria from newborn CD1 mice were collected
and sequentially rinsed in Hank's Balanced Salt Solution
(Invitrogen) and serum-free Minimal Essential Medium
(Invitrogen). Calvaria were digested into a single cell sus-
pension in serum-free alpha- Minimal Essential Medium
containing 2 mg/ml collagenase and 0.25% trypsin. Cells
were washed, plated at 2 × 105 cells/10 cm plate and incu-
bated with HDI as described above.
RNA, cDNA, and biotin-labeled cRNA preparation
To ensure statistical significance of microarray analyses,
quadruplicate cultures of MC3T3-E1 cells were incubated
in osteogenic medium containing DMSO or HDIs. Total
RNA was isolated from each MC3T3-E1 cell culture and
primary calvarial osteoblasts with Trizol reagent (Invitro-
gen). For preparation of GeneChip samples, biotin-
labeled cRNA was prepared from each of the quadrupli-
cate cultures according to the Affymetrix protocol. Briefly,
RNA was denatured at 70°C with T7-oligo (dT) primer
and reverse transcribed using Superscript II at 42°C for 1
hour. Second strand cDNA synthesis was performed by
Venn diagram of differentially expressed genes in TSA, MS- 275, or VPA-treated cells Figure 2
Venn diagram of differentially expressed genes in 
TSA, MS-275, or VPA-treated cells. MC3T3 cells were 
treated with an HDI or DMSO for 18 hours. Affymetrix 
GeneChip microarrays and bioinformatics analysis identified 
genes that were differentially expressed by more than 1.1 
fold in HDI-treated cells relative vehicle (DMSO)-treated 
cells with a FDR of 0.01 (99% confidence).
Table 5: Genes differentially regulated more than two-fold by all three HDIs
Gene Description TSA MS-275 VPA
Induced Fold Change
A kinase anchor protein 12 (Akap12) 9.5 2.0 2.6
Glutaminyl-peptide cyclotransferase (Qpct)* 5.0 2.4 2.3
Glutathione S-transferase, alpha 4 (Gsta4) 8.5 2.3 3.1
Ral GEF with PH domain and SH3 binding motif 2 (Ralgps2) 2.2 2.0 2.1
Solute carrier family 9, isoform 3 regulator 1 (Slc9a3r1)* 5.6 2.5 2.2
Sorbitol dehydrogenase 1 (Sdh1)* 4.5 2.4 2.3
Suppressed
Adaptor-related protein complex AP-4, sigma 1 (Ap4s1) -4.9 -2.5 -2.1
Proteasome (prosome, macropain) subunit, beta type 10 (Psmb10)* -5.4 -2.1 -2.0
All genes were present at a FDR of 0.05 (95% confidence) relative to the vehicle control, DMSO. An asterisk (*) indicates genes present at a FDR 
of 0.01 (99% confidence).BMC Genomics 2007, 8:362 http://www.biomedcentral.com/1471-2164/8/362
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Specificity of HDI-inducible genes Figure 3
Specificity of HDI-inducible genes. MC3T3 and NIH3T3 cells were cultured in osteogenic medium containing TSA or 
DMSO for 18 hours. mRNAs were isolated, reverse transcribed and amplified using semi-quantitative real-time PCR with prim-
ers for Slc9a3r1 (A) or Sdh1 (B), Qpct (C) and Psmb10 (D). Comparative threshold values represent the mean of three sam-
ples normalized to actin levels.BMC Genomics 2007, 8:362 http://www.biomedcentral.com/1471-2164/8/362
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incubating first strand cDNA with Escherichia coli DNA
polymerase I, E. coli. DNA ligase, RNase H, and dNTPs for
2 hours at 16°C. Biotin-labeled cRNA was prepared from
double-stranded cDNA using the Affymetrix GeneChip
IVT Labeling kit (Affymetrix, Santa Clara, CA), then puri-
fied and fragmented using the Affymetrix Sample Cleanup
Module.
Verification of Slc9a3r1 and Sdh1 as HDI-inducible genes Figure 4
Verification of Slc9a3r1 and Sdh1 as HDI-inducible genes. MC3T3 (A and C) or primary calvarial osteoblasts (B and D) 
were cultured in osteogenic medium containing the indicated HDI or DMSO. mRNAs were isolated at various times over a 6 
or 18 hour period and subjected to quantitative real-time PCR with primers for Slc9a3r1 (A and B) or Sdh1 (C and D). Values 
are relative to those obtained from DMSO-treated samples at each time point and represent the mean of three samples. For 
(A-D), * denotes a statistically significant change of p < 0.01 and ** denotes p < 0.05 by one-way ANOVA of the HDI-treated 
sample versus the DMSO-treated sample at that time point. (E) C2C12 cells were cultured in osteogenic medium and 20 nM 
TSA for the indicated times. Slc9a3r1 protein levels were determined by immunoblotting.BMC Genomics 2007, 8:362 http://www.biomedcentral.com/1471-2164/8/362
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Affymetrix genechip
Hybridization of the biotinylated-cRNA to the Affymetrix
GeneChip Mouse Genome 430 2.0 Array was performed
by the BioMedical Genomics Center's microarray facility
at the University of Minnesota using Affymetrix Gene-
chip® Hybridization Oven 640 and Fluidics Station 450.
For each condition, four chips were hybridized. Scanning
of the chips to detect and quantify hybridization signals
was done with the Affymetrix Genechip® Scanner 3000.
The gene expression data were preprocessed and analyzed
by the University of Minnesota Cancer Center Informatics
Shared Resource. Raw data measurements were imported
into Genedata Expressionist®  Refiner (EPro1.0.32) for
overall chip hybridization quality assessment, correction
and condensation of probe sets intensity values. Robust
Multichip Average (RMA) method was applied for global
background subtraction and cross array normalization
[40]. Processed expression data were imported into Gene-
data Expressionist Analyst. General assessment of the data
distribution was performed with Principle Component
Analysis, boxplot and log-log data plots. Following LOESS
normalization, differential expression measures were cal-
culated by Welch test comparisons of control DMSO
(vehicle) versus each HDAC inhibitor. Significant genes
from each comparison were selected using the Benjamini-
Hochberg method to control for a maximum false discov-
ery rate (FDR) of 95% or 99% as indicated. Values for fold
change were calculated and genes demonstrating a net
change in gene expression of two fold or greater were
selected for further analysis.
Table 6: Growth factor and growth factor receptor genes regulated by HDIs
MC3T3 Cells Microarray Primary Osteoblasts qRT-PCR
Growth factor/receptor TSA MS-275 VPA TSA VPA
Fold Change
Amphiregulin 7.10 2.74 1.82 24.8 2.56
Brain-derived neurotrophic factor 2.51 1.66 1.77 ND ND
Fibroblast growth factor 7 -5.80 -1.10 -1.17 -29.9 1.05
Frizzled 1 -2.17 -1.25 -1.24 -2.53 -1.44
Frizzled 4 2.23 1.37 1.53 1.79 2.57
Interleukin 1 receptor-like 1 -1.63 -2.04 -1.83 -52.1 1.04
Interleukin 17 receptor c -2.62 -1.50 -1.43 ND ND
Smoothened -2.60 -1.53 -1.17 ND ND
Cells were incubated with HDIs for 18 hr. All genes were present at a FDR of 0.05 (95% confidence) relative to the vehicle control, DMSO. ND, 
not determined.
Verification of Psmb10 and Ap4s1 as HDI-suppressed genes Figure 5
Verification of Psmb10 and Ap4s1 as HDI-suppressed genes. Primary calvarial osteoblasts were cultured in osteogenic 
medium containing the indicated HDI or DMSO. mRNAs were isolated after 18 hours and subjected to quantitative real-time 
PCR with primers for Psmb10 (A) or Ap4s1 (B). Values are relative to those obtained from DMSO-treated samples at each 
time point and represent the mean of three samples. ** denotes p < 0.05 by one-way ANOVA of the HDI-treated sample ver-
sus the DMSO-treated sample at that time point.BMC Genomics 2007, 8:362 http://www.biomedcentral.com/1471-2164/8/362
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Quantitative real-time PCR
Total RNA was isolated from MC3T3-E1, NIH3T3, and
primary murine calvarial cells with Trizol reagent (Invitro-
gen). RNA (1 µg) was reverse transcribed to cDNA with
the Invitrogen Superscript Kit. cDNA was amplified with
the Qiagen Quantitect SYBR Green RT-PCR kit using gene
specific primers (Table 7) in a MyIQ Single Color Real-
Time PCR Detection System (BioRad). Quantification and
normalization to actin amplicons were performed as pre-
viously described [26]. Statistical analyses were performed
with Prism 4.0 (GraphPad Software, San Diego, CA).
Alkaline phosphatase activity assay
Alkaline phosphatase activity was measured on the indi-
cated days as previously described [26]. Briefly, MC3T3-
E1 cells were washed in PBS, lysed in 0.2% NP-40 and 1
mM MgCl2, sonicated, and spun at 3000 rpm for 15 min-
utes at 4°C. The supernatants were added to a reaction
solution containing 0.6 M 2-amino-2-methyl-1-propanol,
2.4 mM MgCl2, and 9.6 mM p-nitrophenyl phosphate and
incubated at 37°C for 30 minutes, at which time the reac-
tions were stopped with 2N NaOH and the absorbance
read at 410 nm. Alkaline phosphatase activity was nor-
malized to protein content. Protein content was deter-
mined using the DC Protein Assay system (BioRad).
Immunoblotting
Cell lysates were prepared by rinsing cultures with PBS
prior to lysing the cells on ice for 5 minutes in modified
RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM sodium
chloride, 1% NP-40, 0.25% sodium deoxycholate, 1 mM
EDTA) supplemented with complete protease inhibitor
tablets (Roche, Basel, CH). Crude lysates were sonicated
and cleared by centrifugation at 10,000 rpm at 4°C. Total
protein was quantified using the detergent-compatible
protein assay (BioRad, Hercules, CA). Protein (50 µg) was
resolved by SDS-PAGE on an 8% gel and transferred to
Immobilon-P membranes (Millipore, Billerica, MA).
Membranes were sequentially blotted with antibodies
against NHERF1/EBP50 (ab3452; Abcam, Cambridge,
MA) and HRP-conjugated secondary antibodies (Sigma).
Proteins were visualized using ECL-Plus chemilumines-
cent substrate (G.E. Health Systems).
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Table 7: Primer sequences used for PCRs
Gene Strand Primer Sequences Annealing Temp (°C) Product Length (bp)
Akap12 F 5' GCCAGTGAAGAACATGAGCAG 56 160
R 5' CTATGCAATCTGCTTTGTCTTGG
Ap4s1 F 5' GTACTTCAGCCGAGTGAGTG 56 202
R 5' CTCTTCCTTGGCCTTCACAG
Amphiregulin F 5' GACTCACAGCGAGGATGACAAG 56 249
R 5' GCTTGGCAATGATTCAAC
Fibroblast growth factor 7 F 5' CAGTTTGGAAAGAGCGACGAC 56 170
R 5' GGCAGGATCCGTGTCAGTATC
Frizzled-1 F 5' CAAGGTTTACGGGCTCATGTAC 56 180
R 5' GTAACAGCCGGACAGGAAAATG
Frizzled-4 F 5' CTGCAGCATGCCTAATGAGAG 56 185
R 5' CGTCTGCCTAGATGCAATCA
Interleukin 1 receptor-like 1 F 5' CCAGCCAGAGTGGAAGACTC 56.9 189
R 5' CAGGTCAATTGTTGGACACG
Psmb10 F 5' CTTTACTGCCCTTGGCTCTG 56.9 168
R 5' GTGATCACACAGGCATCCAC
Qpct F 5' GAGGAGGCACTGAAGGAGTG 53 162
R 5' GAAGATCGGACTGGATGCTC
Sdh1 F 5' CTGCCGATTCTACAAGCACA 56.9 183
R 5' AGCAAAGTGACCATCCCAAC
Slc9a3r1 F 5' CAAAGTGTCCCCTCACCAGT 56.9 209
R 5' AATGAACCCAAGATGCCAAGBMC Genomics 2007, 8:362 http://www.biomedcentral.com/1471-2164/8/362
Page 13 of 13
(page number not for citation purposes)
References
1. Grunstein M: Histone acetylation in chromatin structure and
transcription.  Nature 1997, 389(6649):349-352.
2. Peterson CL, Laniel MA: Histones and histone modifications.
Curr Biol 2004, 14(14):R546-51.
3. Gray SG, Ekstrom TJ: The Human Histone Deacetylase Family.
Exp Cell Res 2001, 262(2):75-83.
4. Gregoretti IV, Lee YM, Goodson HV: Molecular evolution of the
histone deacetylase family: functional implications of phylo-
genetic analysis.  J Mol Biol 2004, 338(1):17-31.
5. Yang XJ, Gregoire S: Class II histone deacetylases: from
sequence to function, regulation, and clinical implication.
Mol Cell Biol 2005, 25(8):2873-2884.
6. Blander G, Guarente L: The Sir2 family of protein deacetylases.
Annu Rev Biochem 2004, 73:417-435.
7. Yoshida M, Matsuyama A, Komatsu Y, Nishino N: From discovery
to the coming generation of histone deacetylase inhibitors.
Curr Med Chem 2003, 10(22):2351-2358.
8. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS: Histone
deacetylase is a target of valproic acid-mediated cellular dif-
ferentiation.  Cancer Res 2004, 64(3):1079-1086.
9. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K,
Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P,
Krawiec J, Winkler J, Jaye M: Identification of novel isoform-
selective inhibitors within class I histone deacetylases.  J Phar-
macol Exp Ther 2003, 307(2):720-728.
10. Minucci S, Pelicci PG: Histone deacetylase inhibitors and the
promise of epigenetic (and more) treatments for cancer.  Nat
Rev Cancer 2006, 6(1):38-51.
11. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA,
Breslow R, Pavletich NP: Structures of a histone deacetylase
homologue bound to the TSA and SAHA inhibitors.  Nature
1999, 401(6749):188-193.
12. Acharya MR, Sparreboom A, Venitz J, Figg WD: Rational Develop-
ment of Histone Deacetylase Inhibitors as Anti-cancer
Agents: A Review.  Mol Pharmacol 2005.
13. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS: His-
tone deacetylase is a direct target of valproic acid, a potent
anticonvulsant, mood stabilizer, and teratogen.  J Biol Chem
2001, 276(39):36734-36741.
14. Blanchard F, Chipoy C: Histone deacetylase inhibitors: new
drugs for the treatment of inflammatory diseases?  Drug Discov
Today 2005, 10(3):197-204.
15. McKinsey TA, Olson EN: Cardiac histone acetylation--thera-
peutic opportunities abound.  Trends Genet 2004, 20(4):206-213.
16. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG:
Histone deacetylase inhibitors trigger a G2 checkpoint in
normal cells that is defective in tumor cells.  Mol Biol Cell 2000,
11(6):2069-2083.
17. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone
R, Gabrielli B: Histone deacetylase inhibitors specifically kill
nonproliferating tumour cells.  Oncogene 2004,
23(40):6693-6701.
18. Schroeder TM, Westendorf JJ: Histone deacetylase inhibitors
promote osteoblast maturation.  J Bone Miner Res 2005,
20(12):2254-2263.
19. Iwami K, Moriyama T: Effects of short chain fatty acid, sodium
butyrate, on osteoblastic cells and osteoclastic cells.  Int J Bio-
chem 1993, 25(11):1631-1635.
20. Sakata R, Minami S, Sowa Y, Yoshida M, Tamaki T: Trichostatin A
activates the osteopontin gene promoter through AP1 site.
Biochem Biophys Res Commun 2004, 315(4):959-963.
21. Jeon EJ, Lee KY, Choi NS, Lee MH, Kim HN, Jin YH, Ryoo HM, Choi
JY, Yoshida M, Nishino N, Oh BC, Lee KS, Lee YH, Bae SC: Bone
morphogenetic protein-2 stimulates Runx2 acetylation.  J Biol
Chem 2006, 281(24):16502-16511.
22. Lee HW, Suh JH, Kim AY, Lee YS, Park SY, Kim JB: Histone
deacetylase 1-mediated histone modification regulates oste-
oblast differentiation.  Mol Endocrinol 2006, 20(10):2432-2443.
23. Smith E, Frenkel B: Glucocorticoids inhibit the transcriptional
activity of LEF/TCF in differentiating osteoblasts in a glyco-
gen synthase kinase-3beta-dependent and -independent
manner.  J Biol Chem 2005, 280(3):2388-2394.
24. Cho HH, Park HT, Kim YJ, Bae YC, Suh KT, Jung JS: Induction of
osteogenic differentiation of human mesenchymal stem cells
by histone deacetylase inhibitors.  J Cell Biochem 2005.
25. Boer JD, Licht R, Bongers M, Klundert TV, Arends R, Blitterswijk CV:
Inhibition of Histone Acetylation as a Tool in Bone Tissue
Engineering.  Tissue Eng 2006.
26. Schroeder TM, Kahler RA, Li X, Westendorf JJ: Histone deacety-
lase 3 interacts with runx2 to repress the osteocalcin pro-
moter and regulate osteoblast differentiation.  J Biol Chem
2004, 279(40):41998-42007.
27. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus:
NCBI gene expression and hybridization array data reposi-
tory.  Nucleic Acids Res 2002, 30(1):207-210.
28. Qin L, Tamasi J, Raggatt L, Li X, Feyen JH, Lee DC, Dicicco-Bloom E,
Partridge NC: Amphiregulin is a novel growth factor involved
in normal bone development and in the cellular response to
parathyroid hormone stimulation.  J Biol Chem 2005,
280(5):3974-3981.
29. Roman-Roman S, Shi DL, Stiot V, Hay E, Vayssiere B, Garcia T, Baron
R, Rawadi G: Murine Frizzled-1 behaves as an antagonist of the
canonical Wnt/beta-catenin signaling.  J Biol Chem 2004,
279(7):5725-5733.
30. Bretscher A, Chambers D, Nguyen R, Reczek D: ERM-Merlin and
EBP50 protein families in plasma membrane organization
and function.  Annu Rev Cell Dev Biol 2000, 16:113-143.
31. Weinman EJ, Hall RA, Friedman PA, Liu-Chen LY, Shenolikar S: The
Association Of Nherf Adaptor Proteins With G Protein-
Coupled Receptors And Receptor Tyrosine Kinases.  Annu Rev
Physiol 2006, 68:491-505.
32. Sneddon WB, Syme CA, Bisello A, Magyar CE, Rochdi MD, Parent JL,
Weinman EJ, Abou-Samra AB, Friedman PA: Activation-independ-
ent parathyroid hormone receptor internalization is regu-
lated by NHERF1 (EBP50).  J Biol Chem 2003,
278(44):43787-43796.
33. Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S: EBP50, a
beta-catenin-associating protein, enhances Wnt signaling
and is over-expressed in hepatocellular carcinoma.  Hepatol-
ogy 2003, 38(1):178-186.
34. Shenolikar S, Voltz JW, Minkoff CM, Wade JB, Weinman EJ: Tar-
geted disruption of the mouse NHERF-1 gene promotes
internalization of proximal tubule sodium-phosphate
cotransporter type IIa and renal phosphate wasting.  Proc Natl
Acad Sci U S A 2002, 99(17):11470-11475.
35. Glickman MH, Ciechanover A: The ubiquitin-proteasome prote-
olytic pathway: destruction for the sake of construction.  Phys-
iol Rev 2002, 82(2):373-428.
36. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G,
Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR: Selec-
tive inhibitors of the osteoblast proteasome stimulate bone
formation in vivo and in vitro.  J Clin Invest 2003,
111(11):1771-1782.
37. Zhao M, Qiao M, Harris SE, Oyajobi BO, Mundy GR, Chen D:
Smurf1 inhibits osteoblast differentiation and bone forma-
tion in vitro and in vivo.  J Biol Chem 2004, 279(13):12854-12859.
38. Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, Woods C,
Kelley MW, Jiang L, Tasman W, Zhang K, Nathans J: Vascular devel-
opment in the retina and inner ear: control by Norrin and
Frizzled-4, a high-affinity ligand-receptor pair.  Cell 2004,
116(6):883-895.
39. Westendorf JJ, Kahler RA, Schroeder TM: Wnt signaling in oste-
oblasts and bone diseases.  Gene 2004, 341:19-39.
40. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ,
Scherf U, Speed TP: Exploration, normalization, and summa-
ries of high density oligonucleotide array probe level data.
Biostatistics 2003, 4(2):249-264.